{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T01:47:41Z","timestamp":1782092861541,"version":"3.54.5"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":49,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Institute for Personalized Medicine"},{"name":"Foconsci Chemical Industry, dept., Biotechnology"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"DOI":"10.1186\/s13256-026-06079-8","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T08:53:50Z","timestamp":1777884830000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exceptional and typical biomarker responses to AminoTriComplex in metastatic prostate cancer: a case series"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9589-7417","authenticated-orcid":false,"given":"Alexandre","family":"Tavartkiladze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaiane","family":"Simonia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russel J.","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruite","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Okrostsvaridze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinara","family":"Kasradze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pati","family":"Revazishvili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irine","family":"Andronikashvili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pirdara","family":"Nozadze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Givi","family":"Tavartkiladze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rusudan","family":"Khutsishvili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatia","family":"Potskhoraia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"issue":"1","key":"6079_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349. https:\/\/doi.org\/10.3322\/caac.21820.","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"6079_CR2","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","volume":"371","author":"ES Antonarakis","year":"2014","unstructured":"Antonarakis ES, Lu C, Wang H, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371(11):1028\u201338. https:\/\/doi.org\/10.1056\/NEJMoa1315815.","journal-title":"N Engl J Med"},{"issue":"11","key":"6079_CR3","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1001\/jamaoncol.2016.1828","volume":"2","author":"HI Scher","year":"2016","unstructured":"Scher HI, Lu D, Schreiber NA, et al. Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer. JAMA Oncol. 2016;2(11):1441\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2016.1828.","journal-title":"JAMA Oncol"},{"issue":"10","key":"6079_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/s18103249","volume":"18","author":"H Huang","year":"2018","unstructured":"Huang H. Matrix metalloproteinase-9 (MMP-9) as a cancer biomarker and MMP-9 biosensors: recent advances. Sensors Basel. 2018;18(10): 3249. https:\/\/doi.org\/10.3390\/s18103249.","journal-title":"Sensors Basel"},{"issue":"5-6","key":"6079_CR5","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s10585-018-9905-8","volume":"35","author":"ER Pego","year":"2018","unstructured":"Pego ER, Fern\u00e1ndez I, N\u00fa\u00f1ez MJ. Molecular basis of the effect of MMP-9 on the prostate bone metastasis: a review. Clin Exp Metastasis. 2018;35(5\u20136):501\u201316. https:\/\/doi.org\/10.1007\/s10585-018-9905-8.","journal-title":"Clin Exp Metastasis"},{"issue":"3","key":"6079_CR6","doi-asserted-by":"publisher","first-page":"840","DOI":"10.14336\/AD.2022.1010","volume":"14","author":"MF Megerian","year":"2023","unstructured":"Megerian MF, Kim JS, Badreddine J, Hong SH. Melatonin and prostate cancer: anti-tumor roles and therapeutic application. Aging Dis. 2023;14(3):840\u201357. https:\/\/doi.org\/10.14336\/AD.2022.1010.","journal-title":"Aging Dis"},{"issue":"1","key":"6079_CR7","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/1097-0045(200101)46:1<52::AID-PROS1008>3.0.CO;2-Z","volume":"46","author":"SC Xi","year":"2001","unstructured":"Xi SC, Siu SW, Fong SW, Shiu SY. Inhibition of androgen-sensitive LNCaP prostate cancer growth in vivo by melatonin: association of antiproliferative action of the pineal hormone with mt1 receptor protein expression. Prostate. 2001;46(1):52\u201361. https:\/\/doi.org\/10.1002\/1097-0045(200101)46:1%3c52::AID-PROS1008%3e3.0.CO;2-Z.","journal-title":"Prostate"},{"issue":"3","key":"6079_CR8","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1034\/j.1600-079X.2003.00074.x","volume":"35","author":"SY Shiu","year":"2003","unstructured":"Shiu SY, Law IC, Lau KW, Tam PC, Yip AW, Ng WT. Melatonin slowed the early biochemical progression of hormone-refractory prostate cancer in a patient whose prostate tumor tissue expressed MT1 receptor subtype. J Pineal Res. 2003;35(3):177\u201382. https:\/\/doi.org\/10.1034\/j.1600-079X.2003.00074.x.","journal-title":"J Pineal Res"},{"issue":"15","key":"6079_CR9","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1038\/sj.onc.1208490","volume":"24","author":"M Zhang","year":"2005","unstructured":"Zhang M, Latham DE, Delaney MA, Bhupendra CD. Survivin mediates resistance to antiandrogen therapy in prostate cancer. Oncogene. 2005;24(15):2474\u201382. https:\/\/doi.org\/10.1038\/sj.onc.1208490.","journal-title":"Oncogene"},{"issue":"4","key":"6079_CR10","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1002\/cncr.20039","volume":"100","author":"SF Shariat","year":"2004","unstructured":"Shariat SF, Lotan Y, Saboorian H, et al. Survivin expression is associated with features of biologically aggressive prostate carcinoma. Cancer. 2004;100(4):751\u20137. https:\/\/doi.org\/10.1002\/cncr.20039.","journal-title":"Cancer"},{"issue":"11","key":"6079_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0007953","volume":"4","author":"B Wegiel","year":"2009","unstructured":"Wegiel B, Jiborn T, Abrahamson M, et al. Cystatin C is downregulated in prostate cancer and modulates invasion of prostate cancer cells via MAPK\/Erk and androgen receptor pathways. PLoS ONE. 2009;4(11): e7953. https:\/\/doi.org\/10.1371\/journal.pone.0007953.","journal-title":"PLoS ONE"},{"issue":"2","key":"6079_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/ph12020087","volume":"12","author":"SM Soond","year":"2019","unstructured":"Soond SM, Kozhevnikova MV, Townsend PA, Zamyatnin AA Jr. Cysteine cathepsin protease inhibition: an update on its diagnostic, prognostic and therapeutic potential in cancer. Pharmaceuticals (Basel). 2019;12(2): 87. https:\/\/doi.org\/10.3390\/ph12020087.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"4","key":"6079_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3000228","volume":"17","author":"Y Lee","year":"2019","unstructured":"Lee Y, Lahens NF, Zhang S, Dobber J, Weljie AM, Bhogale A. G1\/S cell cycle regulators mediate effects of circadian dysregulation on tumor growth and provide targets for timed anticancer treatment. PLoS Biol. 2019;17(4): e3000228. https:\/\/doi.org\/10.1371\/journal.pbio.3000228.","journal-title":"PLoS Biol"},{"issue":"10","key":"6079_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/nu13103480","volume":"13","author":"C Vasey","year":"2021","unstructured":"Vasey C, McBride J, Penta K. Circadian rhythm dysregulation and restoration: the role of melatonin. Nutrients. 2021;13(10): 3480. https:\/\/doi.org\/10.3390\/nu13103480.","journal-title":"Nutrients"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-026-06079-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-026-06079-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-026-06079-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T01:09:03Z","timestamp":1782090543000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13256-026-06079-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6079"],"URL":"https:\/\/doi.org\/10.1186\/s13256-026-06079-8","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,4]]},"assertion":[{"value":"27 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This case series was nested within a double-blind, placebo-controlled study approved by IRB #CN-2021-11 (Institute for Personalized Medicine, Georgia) and #TX-UT-2021-08 (University of Texas Health Science Center, San Antonio). The parent protocol was approved prior to patient enrollment. All patients provided written informed consent for both study participation and publication of de-identified case details and accompanying images. Serial tumor biopsies were protocol-mandated assessments with specific consent obtained as part of the parent study informed consent process. No identifiable images are included. Adverse events were graded according to CTCAE v5.0.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patients for publication of this case series and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AT is affiliated with Foconsci Chemical Industry (Department of Biotechnology), which provided the study product. No patents related to AminoTriComplex are held by any author. All other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This case series adheres to the CARE (CAse REport) guidelines; a completed CARE checklist is provided as supplementary material.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"CARE checklist"}}],"article-number":"336"}}